Trentin, A. G., M. Alvarez-Silva, and V. Moura Neto. Thyroid hormone induces cerebellar astrocytes and C6 glioma cells to secrete mitogenic growth factors. Am J Physiol Endocrinol Metab 281: E1088-E1094, 2001.-In this study, the effect of thyroid hormone (triiodothyronine, T3) on the secretion of mitogenic growth factors in astrocytes and C6 glioma cells was examined. The proliferating activity of T3 could be due, at least in part, to the astrocyte secretion of acidic and basic fibroblast growth factor (aFGF and bFGF), tumor necrosis factor-␤, and transforming growth factor-␤. In contrast, the conditioned medium (CM) of T 3-treated C6 cells was mitogenic to this cell line only after hyaluronidase digestion, suggesting the impairment of growth factor mitogenic activity by hyaluronic acid. Furthermore, the presence of bFGF was significantly greater in the CM of both T 3-treated astrocytes and T 3-treated C6 cells than in the corresponding control CM. These data show that T 3 induces cerebellar astrocytes to secrete mitogenic growth factors, predominantly bFGF, that could influence astrocyte and neuronal proliferation via autocrine and paracrine pathways. cell proliferation; cell differentiation; fibroblast growth factors; interleukin-3 THYROID HORMONE (triiodothyronine, T 3 ) plays an important role in ensuring normal mammalian brain maturation. In the rat, the absence of T 3 during the critical first 3 wk of neonatal life results in retardation and disturbance of normal cellular differentiation (29). T 3 increases proliferation of stem cells from the central nervous system both in vivo and in vitro (13, 20) and controls the astrocyte number and maturation of Bergmann glia in the cerebellum (4). Even though the regulatory role of T 3 in brain development is well established, the cellular and molecular mechanisms by which this hormone produces its biological effects remain elusive.
THYROID HORMONE (triiodothyronine, T 3 ) plays an important role in ensuring normal mammalian brain maturation. In the rat, the absence of T 3 during the critical first 3 wk of neonatal life results in retardation and disturbance of normal cellular differentiation (29) . T 3 increases proliferation of stem cells from the central nervous system both in vivo and in vitro (13, 20) and controls the astrocyte number and maturation of Bergmann glia in the cerebellum (4) . Even though the regulatory role of T 3 in brain development is well established, the cellular and molecular mechanisms by which this hormone produces its biological effects remain elusive.
Astroglial cells are heterogeneous with respect to their ability to respond to T 3 , including their capacity to secrete different growth factors or related molecules. T 3 regulates protein expression in the rat C6 cells (34) , which are immortalized glial cells with properties of both astrocytes and oligodendrocytes (39) . The growth factors secreted by cerebral hemisphere astrocytes, after T 3 stimulation, promote morphological differentiation in these cells derived from both normal and hypothyroid newborn rats. In contrast, T 3 induces cerebellar astrocyte secretion of growth factors responsible for cerebellar astrocyte autocrine proliferation instead of morphological changes (21, 35, 36, 37) . This effect is accompanied by the reorganization of glial fibrillary acidic protein (GFAP), fibronectin (36) , and laminin (7) filaments, thus suggesting a possible additional role of T 3 in cerebellar astrocyte adhesion. In addition, the growth factors secreted by cerebellar astrocytes after T 3 stimulation modulate neuronal proliferation (11) . Hence, the aim of the present study was to identify the mitogenic growth factors secreted by cerebellar astrocytes and rat C6 glioma cells after T 3 stimulation.
MATERIALS AND METHODS

Materials
Cell cultures. Primary cultures of astrocytes were prepared from cerebella obtained from 2-to 3-day-old Wistar rats as described (34) (35) (36) (37) . Cells were grown to semiconfluence (7-8 days) in the presence of Dulbecco's modified Eagle's medium and nutrient mixture F-12 (DMEM-F-12, Sigma, St. Louis, MO) supplemented with 10% fetal calf serum (FCS; Fazenda Pigue, Rio de Janeiro, Brazil). The cultures were incubated at 37°C in a humidified 5% CO 2-95% air atmosphere.
The C6 cell line was grown in the presence of DMEM (Sigma) supplemented with 10% FCS. The cultures were incubated at 37°C in a humidified 5% CO 2-95% air atmosphere. Cells were harvested with trypsin (0.125%, Sigma) when they reached confluence.
Cell treatment and conditioned medium preparation. After confluence, astrocyte or C6 monolayers were washed three times with serum-free DMEM-F-12 and treated with 50 nM 3,3Ј,5-triiodo-L-thyronine (T3) in DMEM-F-12 for 3 days, with medium renewed every day except after the 3rd day. The hormone solution was dissolved in DMEM-F-12 without FCS.
Control cultures were maintained in DMEM-F-12 without FCS. Control and hormone-treated cultures were then maintained for 2 days without medium changes. The conditioned medium (CM) obtained from control (CCM) and T 3-treated cells (T3CM) was collected on the 2nd day after the end of T3 treatment, filtered in nitrocellulose membrane (0.22 m, Millipore), and stored at Ϫ20°C for later use.
Antibodies. Antibody anti-T 3 (1:6,000, Sigma) was used in the evaluation of T3 content in T3CM by RIA and biological activity analysis.
For CM neutralization assays, neutralizing antibodies to growth factors were added to the CMs: rabbit anti-fibroblast growth factor-acidic (anti-aFGF, 1:200; Sigma); rabbit antifibroblast growth factor-basic (anti-bFGF, 1:450; Sigma); rabbit anti-tumor necrosis factor-␤ (anti-TNF-␤, 1:3,500; Sigma); mouse anti-transforming growth factor-␤ (anti-TGF-␤, 1:1,000; a gift from Dr. R. Borojevic, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil), mouse anti-interleukin-3 (anti-IL-3, 1:5,000; Sigma), and mouse anti-granulocyte macrophage colony-stimulating factor (anti-GM-CSF, 1:800; Sigma). Dilution curves were done to verify the ideal dilution of antibodies to neutralize the growth factors' mitogenic activity (Table 1) . We tested by ELISA the activity of the antibodies in the presence of recombinant growth factors, and any cross-reactivity was observed (data not shown).
Quantitative Analysis of Astrocyte and C6 Number
C6 monolayers were cultured in 96-well culture plates and treated with DMEM-F-12 or 50 nM T 3 as described. After 4 days, the monolayers were washed with PBS, trypsinized (0.125%), and counted in a hemocytometer under a Zeiss optic microscope.
Astrocytes were cultured in 24-well culture plates and treated with DMEM-F-12 or 50 nM T 3 as described. After 4 days, the monolayers were fixed and stained with 1% toluidine blue solution in PBS for 5 min, and the cell number was quantified. At least eight fields were counted per well.
Cell Proliferation Monitoring
MTT assay. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay method has been extensively used to determine glial cell proliferation (5, 36, 37) and as an in vitro test system for T 3 action (14) . C6 cells were plated (10 4 cells/well) in 96-well culture plates and cultured for 4 days. Viable cells were quantified by MTT colorimetric assay for mitochondrial dehydrogenase, as previously described (22) . Results were expressed in absorbance at 550 nm.
Primary cerebellar astrocyte cultures were prepared in 96-well culture plates as described and were maintained in DMEM-F-12 enriched with 10% FCS for 4 days until the cells reached semiconfluence. After that, the astrocyte cultures were extensively washed with PBS and submitted to the experimental conditions (described in figure legends). After 4 days, viable cells were quantified by MTT colorimetric assay as described.
Bromodeoxyuridil incorporation and detection. Alternatively, the cell proliferation was analyzed by 5-bromo-2Ј-deoxyuridine (BrdU) incorporation. Astrocyte and C6 cultures were incubated for 24 h in the presence of 1 g/ml of BrdU (Sigma). The cells were fixed with 4% paraformaldehyde for 20 min. Cultures were washed twice with distilled water and then incubated twice in 2 N HCl at 50°C for 15 min. After that, cultures were washed twice with 0.1 M borate buffer for 10 min at room temperature. The cells were then immunoreacted with anti-BrdU antibody (as described in Sytox green nucleic acid stain) and visualized under an epifluorescent Olympus microscope (Olympus, Tokyo, Japan). The mitotic index was measured by counting the percentage of labeled cells in at least eight different fields per coverslip.
Immunofluorescence. The immunofluorescence was performed as described previously (36, 37) . After the BrdU procedure, the monolayers were washed with PBS and permeabilized with 0.2% Triton X-100 for 5 min at room temperature. Cells were incubated with 10% normal goat serum (Sigma) in PBS for 1 h and subsequently with rat anti-BrdU antibody (1:500; Accurate Chemical and Scientific, Westbury, NY). The cells were then washed in PBS and incubated with goat anti-rat antibody conjugated with biotin (1:400; Vector Laboratories, Burlingame, CA). The secondary antibody was revealed by incubation with Texas red-streptavidin conjugate according to the manufacturer's instructions (Vector Laboratories). In all cases, no reactivity was observed when the primary antibody was absent. Cell nuclei were stained with diaminophenylindole (DAPI, Sigma). The cultures were mounted on N-propyl-gallate-glycerol and examined under an epifluorescent Olympus microscope.
Sytox green nucleic acid stain. The astrocyte and C6 monolayers were washed with HEPES buffer (5 mM HEPES; 125 mM NaCl; 5.5 mM KCl; 1.0 mM MgCl2 ⅐ 6H20, 1.8 mM CaCl2 ⅐ 2H20), pH 7.4, and incubated during 10 min with Sytox green nucleic acid stain according to the manufacturer's instructions (Molecular Probes, Eugene, OR). Cells were then washed with PBS and fixed with 4% paraformaldehyde for 20 min. Cell nuclei were stained with DAPI. The cultures were mounted on N-propyl-gallate-glycerol and examined under an epifluorescent Olympus microscope. Eight fields were counted for each well of experiment. Results are expressed as means Ϯ SD of 3 independent experiments performed in quadruplicate. aFGF, acidic fibroblast growth factor; bFGF, basic FGF; TGF-␤, transforming growth factor-␤; TNF-␤, tumor necrosis factor-␤; GM-CSF, granulocyte macrophage colony-stimulating factor. C6 cells were cultured with astrocyte thyroid hormone (T3)-treated conditioned medium (T3CM), and the cell proliferation was measured by MTT assay.
ELISA. The ELISA was performed as previously described (1) . The proteins of CCM and T 3CM were lyophilized and quantified by Bradford's method (3). MaxiSorb immunoplates were preincubated overnight at 4°C with 2 g/well of CCM or T3CM protein or with 0.2 to 100 ng/well of recombinant bFGF (rbFGF, GIBCO-BRL, Grand Island, NY) dissolved in PBS. They were washed and subsequently incubated for 1 h at 37°C with PBS containing 0.1% Tween 20 (Sigma) and 2% bovine serum albumin (Sigma), washed again, and reacted with polyclonal antibody against bFGF (1:2,000, Sigma). The immune reaction was quantified by peroxidase-labeled antiIgG rabbit antibody (Sigma).
C6 CM digestion. C6 CCM or T 3CM was prepared as described in Cell treatment and conditioned medium preparation. The CMs were digested with hyaluronidase (100 mU/ ml, Sigma) or with hyaluronidase (100 mU/ml) plus heparitinase III (10 mU/ml, Sigma) for 15 h at 37°C in a humidified 5% CO 2-95% air atmosphere as described (2) . The CMs were then sterilized by filtration in nitrocellulose membrane (0.22 m, Millipore) and were either used immediately or stored at Ϫ20°C for later use.
Statistical Analysis
Differences between the groups were evaluated by ANOVA and Student's t-test, and the differences were considered significant at P Ͻ 0.05.
RESULTS
T 3 Stimulates Cerebellar Astrocyte and C6 Glioma Cell Proliferation
We further investigated the effects of T 3 and CM from T 3 -treated cerebellar astrocyte (T 3 CM) treatments on proliferation of cerebellar astrocytes and C6 glioma cells. We verified that both T 3 and T 3 CM induced significant astrocyte proliferation by MTT assay or direct cell counting (Table 2 ). In addition, Ͼ95% of the cells were GFAP positive before and after both treatments, attesting to their astrocyte phenotype (36, 37) . These results are in agreement with our previous data (36, 37) and suggest that the secretion of mitogenic growth factors may promote the T 3 effects on astrocyte proliferation. In our culture conditions, these proliferative effects were not directly mediated by T 3 , since no residual hormone was detected (by RIA) in the CM of hormone-treated cultures (37) . Alternatively, the anti-T 3 antibody did not alter the mitogenic effect of T 3 CM (data not shown). We also verified that T 3 induced significant C6 cell proliferation, with the maximum effect obtained at 50 nM (Table 2) .
To investigate whether astrocyte and C6 population augmentation was due to increased proliferation or survival, we tested the BrdU incorporation. As shown in Table 2 , the incorporation of BrdU was at least four times higher in T 3 -treated and T 3 CMtreated astrocytes than in control cells, confirming that T 3 plus CM stimulates cerebellar astrocyte proliferation instead of cell survival. In addition, we verified that T 3 -treated C6 cells incorporated 30% more BrdU than the controls. However, T 3 CM from C6 cells did not promote a significant increase in C6 proliferation ( Table 2) .
To analyze the proportion of cell mortality in our culture conditions, we performed incubations with Sytox green. As shown in Table 2 , the proportion of Sytox green-positive astrocytes and C6 glioma cells was very low in all treatments, indicating that the cell mortality was insignificant in our experiments. In addition, we could observe an increase in DAPI-positive cells in both T 3 (61%) and T 3 CM-treated (69%) astrocytes and in T 3 -treated (50%) C6 cells when compared with controls (data not shown).
Cerebellar Astrocyte CM Induces Astrocyte Proliferation
To analyze the growth factors involved in astrocyte proliferation, some commercial neutralizing antibodies against growth factors were added to the CMs. We verified that the addition of anti-bFGF to the T 3 CM promoted the more significant inhibition in astrocyte proliferation (40%); however, anti-aFGF (23%) and anti-TNF-␤ (29%) also presented significant inhibitory effects compared with the CCM (Fig.  1A) . To test the additive effect on these growth factors, anti-aFGF, anti-bFGF, and anti-TNF-␤ were added together. As a result we obtained 65% inhibition in astrocyte proliferation (data not shown). We also observed a basal astrocyte production of TGF-␤, because the addition of the neutralizing antibody partially inhibited the mitogenic effect of both CCM and T 3 CM when compared with the corresponding CM without antibody (Fig. 1A) . 
Cerebellar Astrocyte CM Induces C6 Cell Proliferation
To verify whether the soluble factors secreted by cerebellar astrocytes after T 3 stimulation are also mitogenic to C6 cells, proliferating experiments with the use of T 3 CM from cerebellar astrocytes were performed.
As shown in Fig. 2 , astrocyte T 3 CM induced a significant dose-dependent increase in C6 cell proliferation. The proportion of 50% of astrocyte T 3 CM was the initial CM concentration necessary to promote a significant increase in C6 proliferation compared with astrocyte CCM. This result indicated that the growth factors secreted by cerebellar astrocyte after thyroid hormone stimulation were also mitogenic to C6 cells.
To analyze the mitogenic growth factor(s) involved in C6 proliferation, CCM and T 3 CM from astrocytes were incubated with neutralizing antibodies to known growth factors (Fig. 1B) . We observed significant inhibition in C6 cell proliferation after the addition of anti-bFGF (35%) or anti-IL-3 (16.5%) to the astrocyte T 3 CM compared with CCM (Fig. 1B) . Interestingly, anti-aFGF and anti-TGF-␤ significantly inhibited the mitogenic effect of only astrocyte T 3 CM compared with the same CM without antibody but not compared with the corresponding CCM, suggesting a basal astrocyte secretion of these growth factors (Fig. 1B) . In addition, C6 cultures treated with astrocyte CCM presented a significant inhibition of proliferation after the addition of neutralizing anti-bFGF compared with the same CM without antibody, also suggesting a basal concentration of bFGF.
C6 Cell CM Effects on C6 Proliferation
The preceding results in this study suggest that the T 3 and astrocyte T 3 CM mitogenic action is similar in both C6 cells and astrocytes. However, T 3 CM from C6 cells was not effective in promoting C6 cell proliferation (Table 2) .
Hyaluronic acid is a negatively charged, high-molecular-weight polysaccharide that forms strikingly viscous solutions (19) and is overexpressed in tumor cells (32) . In our culture conditions, we observed that the C6 CM was very viscous. We hypothesized that C6 cells secreted a very large amount of hyaluronic acid, which accumulated in the culture dish, interfering with growth factor activity. To test this hypothesis, we digested C6 CM with hyaluronidase or hyaluronidase plus heparitinase III and observed the recovery of mitogenic activity. As shown in Fig. 3 , digested or nondigested C6 CCM had no effect on C6 proliferation. As expected, nondigested C6 T 3 CM did not induce C6 cell proliferation; however, a significant increase in C6 proliferation was observed when T 3 CM from C6 cells was digested by hyaluronidase.
In addition, anti-bFGF was added to the T 3 CM from C6 cells previously digested by hyaluronidase, and the proliferative activity was partially abolished (Fig. 3) . Heparitinase III digestion also impaired the recovery of the proliferative effect of the C6 T 3 CM promoted by hyaluronidase (Fig. 3) .
Heparin and C6 Proliferation
It has been demonstrated that heparin enhances the activity of the FGFs (31) and that its excess reduces the growth factor action (18) . To verify whether these effects could be observed in our experimental model, a heparin concentration curve was performed with C6 cells (Fig. 4) . The addition of low concentrations of heparin (0.1, 0.5, 1, or 10 ng/ml) to the 50 nM T 3 solution stimulated C6 proliferation, and as expected, the higher concentrations (50 or 70 ng/ml) inhibited it.
bFGF Quantification
The aforementioned experiments with growth factors neutralizing antibodies suggest that the bFGF may be the main factor present in the CM from both astrocytes and C6 cells. To quantify this growth factor, we performed ELISA assays (Fig. 5) . We verified a significant increase in bFGF production in T 3 CM of both astrocytes (eightfold) and C6 cells (twofold) compared with the corresponding CCM.
DISCUSSION
We had previously shown that T 3 induces the synthesis and secretion of growth factors by cerebellar astrocytes that mediate the T 3 proliferative effect (21, 36, 37) . In addition to astrocyte proliferation, these growth factors are also mitogenic to cerebellar neuronal cells (11) , suggesting autocrine and paracrine mechanisms underlying the proliferative T 3 mode of action.
The main finding of the present study is the demonstration that astrocytes secrete a cocktail of growth factors that mediate the mitogenic effect of T 3 on cerebellar astrocytes and C6 cells. BrdU and Sytox green incorporation clearly point to the proliferative activity of T 3 and astrocyte T 3 CM instead of cell survival.
T 3 induces cerebellar astrocytes to secrete a combination of growth factors, among them bFGF, aFGF, TNF-␤, and IL-3, that are partially responsible for the astrocyte and C6 cell proliferation. These growth factors may act coordinately. Therefore, bFGF seems to be the principal mitogenic growth factor secreted by cerebellar astrocytes after T 3 stimulation. However, some antibodies (anti-bFGF, anti-aFGF, and anti-TGF-␤) inhibited the astrocyte or C6 cell proliferation in a mechanism independent of the T 3 action, suggesting that the basal secretion of these growth factors by astrocytes may occur.
It was reported that TNF induces astrocyte proliferation in a time-and dose-dependent manner, accompanied by downregulation of GFAP mRNA (24) . TNF is also mitogenic to C6 glioma cells, increasing the expression of TNF type II receptor (16) . Recently, TNF-␤ (also known as lymphotoxin-␣) was shown to be involved in the T 3 effects on neuronal proliferation (11) . In our experiments, anti-TNF-␤ markedly reduced astrocyte, but not C6 cell, proliferation. On the other hand, Frei et al. (8) reported an IL-3-like factor that was produced by astrocyte exposure to lipopolysaccharide. However, there is a divergence concerning IL-3 production in the central nervous system (17, 25) . Our results could suggest an involvement of IL-3 on the T 3 mode of action, because the anti-IL-3 antibody significantly inhibited C6 cell proliferation without effects on astrocytes. However, this finding must be further explored. The differential effects of the neutralizing growth factor antibodies on C6 cells and cerebellar astrocyte proliferation may be explained by differences in the metabolism of these two cell types.
The members of the FGF family are found in developing and adult rat brain and are heparin-binding growth factors (27) . bFGF affects the proliferation and differentiation of glial precursor cells (38) and, in vitro, stimulates the proliferation and migration of neonatal rat astrocytes (6, 15) . The expression of bFGF has been shown to be elevated in tissue specimens from gliomas, meningiomas, and metastatic brain tumors (23) , and antisense oligonucleotides to bFGF can inhibit the growth of transformed human astrocytes (10) . C6 cells (30) and cerebellar astrocytes (12) have been demonstrated to synthesize bFGF protein. Furthermore, aFGF and bFGF are suggested to regulate both the activation and inactivation of T 3 metabolism in brain (28) .
It has been reported that the activity of FGF is modulated by extracellular matrix molecules (9, 31) and that the high amounts of negatively charged polysaccharides impairs interaction of growth factors with their receptors on the cell surface (1, 2) . It is well known that hyaluronic acid production is high during cell proliferation and migration (33) and in the developing brain (26) . In our experiments, the T 3 CM from C6 cells was ineffective in promoting cell proliferation. The digestion by hyaluronidase recovered its mitogenic activity, which was impaired by anti-bFGF or heparitinase III digestion. These data suggest that T 3 stimulates bFGF secretion in C6 cells and large amounts of hyaluronic acid in C6 cultures, interfering with the growth factor mitogenic activity. The digestion of heparan sulfate chains by hyaluronidase activity also affected C6 proliferation, possibly because heparan sulfate chains are crucial to bFGF activity (40) and bind to hyaluronic acid (9) . Our results may suggest the occurrence of a bFGF reservoir in the extracellular matrix through proteoglycans and hyaluronic acid in C6 cell cultures after T 3 treatment.
Previous studies have shown that heparin increases the affinity of bFGF for its receptor (31) and, in excess, competes for the binding sites within the signaling complex, and receptor transphosphorylation is reduced (18) . In our experiments, we could demonstrate the stimulatory and inhibitory effects of heparin on T 3 -mediated C6 proliferation. Endogenous heparan sulfate may modulate the action of the FGF secreted by T 3 stimulation in C6 cultures.
The presence of bFGF in both astrocyte and C6 T 3 CM was confirmed by ELISA. T 3 stimulation increased eight times the bFGF secretion by astrocytes and two times by C6 cells. However, C6 CCM presented a basal concentration of bFGF that may be responsible for the C6 basal proliferation. The lower amount of bFGF in C6 T 3 CM may explain its lower proliferative effect. Our data strongly suggest that bFGF is the main growth factor that mediates the T 3 mitogenic effect in cerebellar astrocytes and C6 cells. At least in C6 cells, its mitogenic activity may be directed by extracellular molecules such as heparan sulfate and/or hyaluronic acid.
